This inventor holds 4 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Glaxosmithkline Intellectual Property Development Limited, Cancer Research Technology Limited. Active years: 2021-2025.
Company Filing History:
4 out of 242 
1 out of 268 Years Active: 2021-2025
Title: The Innovative Contributions of David T. Fosbenner
Introduction
David T. Fosbenner is a notable inventor based in Collegeville, PA (US), recognized for his significant contributions to the field of pharmaceuticals. He holds a total of four patents, showcasing his dedication to advancing medical science and treatment options.
Latest Patents
Among his latest innovations are patents related to substituted pyridines as DNA methyltransferase 1 (DNMT1) inhibitors. These inventions focus on substituted pyridine derivatives that inhibit the activity of DNMT1. The patents also encompass pharmaceutical compositions that include these compounds and methods for their use in treating cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, and other diseases linked to inappropriate DNMT1 activity.
Career Highlights
David has worked with prominent organizations such as GlaxoSmithKline Intellectual Property Development Limited and Cancer Research Technology Limited. His work in these companies has contributed to the development of innovative treatments and therapies.
Collaborations
Some of his notable coworkers include Bryan Wayne King and Stuart Paul Romeril, who have collaborated with him on various projects throughout his career.
Conclusion
David T. Fosbenner's work exemplifies the impact of innovation in the pharmaceutical industry, particularly in the development of treatments for serious health conditions. His patents and collaborations highlight his commitment to improving patient outcomes through scientific advancement.